NASDAQ:ADXS Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free ADXS Stock Alerts $0.64 -0.06 (-8.57%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.64▼$0.7250-Day Range$0.52▼$1.3152-Week Range$0.51▼$1.95Volume16,416 shsAverage Volume11,105 shsMarket Capitalization$6.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Get Ayala Pharmaceuticals alerts: Email Address Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Read More ADXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADXS Stock News HeadlinesMarch 26, 2024 | globenewswire.comAyala Pharmaceuticals Announces Completion of Sale of AL102 to ImmunomeMarch 23, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)March 29, 2024 | WealthPress (Ad)The ProTrader Dashboard is simple to use! (trade demo inside)Top traders like Kathy, Philip, Matt and Michael made out like bandits… “Took 65% profit on VFC today! Thanks!” - Kathy L. “Made 72% on VFC” - Philip “VFC was good, made $1,000 bucks” - Matt (estimated starting stake $1K) “VFC crushed it… Up 114% for a $3,249 profit!” - Michael It’s all thanks to the all-new ProTrader Dashboard… And today’s your chance to become one of the lucky ones to discover it for yourself.March 16, 2024 | finance.yahoo.comIMNM Oct 2024 22.500 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 putMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 45.000 callFebruary 20, 2024 | businesswire.comImmunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 10, 2024 | msn.comAdvaxis Executes Strategic Unregistered Equity SalesFebruary 7, 2024 | msn.comAdvaxis Announces Definitive Agreement with Ayala PharmaceuticalsFebruary 6, 2024 | msn.comImmunome to buy AL102, a phase 3 asset for treatment of desmoid tumorsFebruary 6, 2024 | finance.yahoo.comImmunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala PharmaceuticalsNovember 24, 2023 | morningstar.comAyala Pharmaceuticals Inc Ordinary Shares ADXSNovember 20, 2023 | sfgate.comAyala Pharmaceuticals: Fiscal Q4 Earnings SnapshotNovember 17, 2023 | msn.comLadenburg Thalmann Downgrades Ayala Pharmaceuticals (ADXS)October 23, 2023 | finance.yahoo.comAyala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023October 19, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Closing of Merger with BiosightAugust 10, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | investing.comAyala Pharmaceuticals Inc (ADXS)August 1, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023July 27, 2023 | finance.yahoo.comAyala Pharmaceuticals and Biosight Enter into Definitive Merger AgreementJuly 5, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid TumorsJune 5, 2023 | finance.yahoo.comUpdated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 20, 2023 | health.usnews.comArmando AyalaSee More Headlines Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/09/2021Today3/29/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADXS CUSIPN/A CIK1100397 Webwww.ayalapharma.com Phone609-452-9813Fax609-452-9818EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax Margin-210,876.91% Return on Equity-2,798.92% Return on Assets-195.41% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$3.24 million Price / Sales2.12 Cash FlowN/A Price / Cash FlowN/A Book Value($0.61) per share Price / Book-1.05Miscellaneous Outstanding Shares10,750,000Free Float10,684,000Market Cap$6.88 million OptionableNot Optionable Beta1.65 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Ruth Ben Yakar Ph.D. (Age 54)Chief Exec. Officer Dr. Stela Gangrenovitch Ph.D.Co-Founder, Chief Scientist Officer and DirectorMr. Mark Gengrinovitch LLBCo-Founder, Chief Financial Officer and DirectorKey CompetitorsPasithea TherapeuticsNASDAQ:KTTAHillstream BioPharmaNASDAQ:HILSShuttle PharmaceuticalsNASDAQ:SHPHAlzamend NeuroNASDAQ:ALZNLixte BiotechnologyNASDAQ:LIXTView All Competitors ADXS Stock Analysis - Frequently Asked Questions Should I buy or sell Ayala Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXS, but not buy additional shares or sell existing shares. View ADXS analyst ratings or view top-rated stocks. How have ADXS shares performed in 2024? Ayala Pharmaceuticals' stock was trading at $0.6670 at the beginning of the year. Since then, ADXS stock has decreased by 4.0% and is now trading at $0.64. View the best growth stocks for 2024 here. When is Ayala Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our ADXS earnings forecast. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) posted its quarterly earnings data on Thursday, September, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company had revenue of $0.25 million for the quarter. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX). How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADXS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.